Article Information
History
- January 4, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Paul B. Finn1,2,#,
- Michael Chavez1,#,
- Xinyi Chen1,
- Haifeng Wang1,
- Draven A. Rane1,
- Jitendra Gurjar2,4 and
- Lei S. Qi1,2,3,*
- 1Department of Bioengineering, Stanford University, Stanford, CA, USA
- 2Sarafan ChEM-H, Stanford University, Stanford, CA, USA
- 3Chan Zuckerberg Biohub, San Francisco, CA, USA
- 4Novartis Institutes for BioMedical Research, San Diego, CA, USA
- ↵*Corresponding to: stanley.qi{at}stanford.edu (L.S.Q)
↵# Equal contribution
Posted January 04, 2023.
Programmable Drug Control of Receptor Valency Modulates the Potency of Cell Therapeutics
